PMID- 30641803
OWN - NLM
STAT- MEDLINE
DCOM- 20190425
LR  - 20190425
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 13
IP  - 1
DP  - 2019 Jan-Feb
TI  - Plasma endoglin in Type2 diabetic patients with nephropathy.
PG  - 764-768
LID - S1871-4021(18)30507-1 [pii]
LID - 10.1016/j.dsx.2018.11.058 [doi]
AB  - BACKGROUND: Diabetic nephropathy may be a common complication of diabetes 
      mellitus. Endoglin is glycoprotein located on cell surfaces of endothelial cells 
      and is part of the transforming growth factor beta (TGF- beta) receptor. Endoglin 
      expression is enhanced in endothelial cells during injury and inflammation. The 
      aim of this study was to estimate the plasma level of soluble endoglin (sEng) in 
      type 2 diabetic patients (with and without nephropathy). Also to explore its 
      availability as marker for disease progression. METHODS: In this study, sixty 
      eight patients with type 2 diabetes mellitus (T2DM) were included; the patients 
      were sub-grouped to normoalbuminuria without nephropathy and moderately increased 
      albuminuria (microalbuminuria) with nephropathy groups with 13 individuals as 
      control group. Plasma soluble endoglin level was determined using ELISA 
      technique. Fasting plasma glucose (FPG), glycated haemoglobin (HbA1c), lipid 
      profile, and creatinine were determined using colorimetric assay, whereas 
      glomerular filtration rate (GFR) was calculated. RESULTS: The plasma level of 
      sEng of both normoalbuminuria group 1 and microalbuminuria group 2 were 
      significantly higher when compared to control group. While, the plasma level of 
      sEng in microalbuminuria group 2 was nonsignificant lower when compared to 
      normoalbuminuria group 1. Also, there was a significant positive association 
      between plasma level of sEng and HbA1c, HDL-C and urinary albumin concentration 
      in normoalbuminuria group. CONCLUSION: Plasma level of soluble Endoglin is 
      markedly increase prior to alteration in endothelial function, and increases to 
      lesser extent with the developing of diabetic nephropathy which indicated disease 
      progression and development of vascular abnormalities.
CI  - Copyright (c) 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.
FAU - Doghish, Ahmed S
AU  - Doghish AS
AD  - Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, 
      13465, Cairo, Egypt; Biochemistry Department, Faculty of Pharmacy, Badr 
      University in Cairo, Cairo, Egypt. Electronic address: 
      ahmed_doghish@azhar.edu.eg.
FAU - Bassyouni, Atef A
AU  - Bassyouni AA
AD  - National Institute of Diabetes and Endocrinology (NIDE), Cairo, Egypt.
FAU - Mahfouz, Mohamed H
AU  - Mahfouz MH
AD  - National Institute of Diabetes and Endocrinology (NIDE), Cairo, Egypt.
FAU - Abd El-Aziz, Heba G
AU  - Abd El-Aziz HG
AD  - Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, 
      13465, Cairo, Egypt.
FAU - Zakaria, Rania Y
AU  - Zakaria RY
AD  - Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, 
      13465, Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20181205
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (Biomarkers)
RN  - 0 (ENG protein, human)
RN  - 0 (Endoglin)
SB  - IM
MH  - Biomarkers/blood
MH  - Diabetes Mellitus, Type 2/*blood/*diagnosis
MH  - Diabetic Nephropathies/*blood/*diagnosis
MH  - Endoglin/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Diabetic nephropathy
OT  - Microalbuminuria
OT  - Normoalbuminuria
OT  - Soluble endoglin
EDAT- 2019/01/16 06:00
MHDA- 2019/04/26 06:00
CRDT- 2019/01/16 06:00
PHST- 2018/10/23 00:00 [received]
PHST- 2018/11/30 00:00 [accepted]
PHST- 2019/01/16 06:00 [entrez]
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2019/04/26 06:00 [medline]
AID - S1871-4021(18)30507-1 [pii]
AID - 10.1016/j.dsx.2018.11.058 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2019 Jan-Feb;13(1):764-768. doi: 10.1016/j.dsx.2018.11.058. 
      Epub 2018 Dec 5.